Wells Fargo & Company Cuts iRhythm Technologies (NASDAQ:IRTC) Price Target to $200.00

iRhythm Technologies (NASDAQ:IRTC) had its target price decreased by Wells Fargo & Company from $225.00 to $200.00 in a research note issued to investors on Friday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Other research analysts have also issued reports about the company. Freedom Capital raised iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. lifted their price objective on shares of iRhythm Technologies from $190.00 to $240.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Loop Capital set a $220.00 target price on shares of iRhythm Technologies in a research note on Friday, October 31st. Canaccord Genuity Group lifted their price target on shares of iRhythm Technologies from $193.00 to $212.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Robert W. Baird dropped their price target on iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, iRhythm Technologies has an average rating of “Moderate Buy” and a consensus target price of $211.62.

iRhythm Technologies Trading Down 5.0%

Shares of NASDAQ:IRTC opened at $150.96 on Friday. The company has a 50 day moving average of $164.65 and a 200-day moving average of $171.48. The company has a current ratio of 4.63, a quick ratio of 4.48 and a debt-to-equity ratio of 4.25. The firm has a market cap of $4.88 billion, a P/E ratio of -107.83 and a beta of 1.06. iRhythm Technologies has a twelve month low of $92.52 and a twelve month high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last announced its earnings results on Thursday, February 19th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.02 by $0.27. The firm had revenue of $208.89 million for the quarter, compared to analysts’ expectations of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The firm’s quarterly revenue was up 27.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) earnings per share. As a group, analysts anticipate that iRhythm Technologies will post -1.98 earnings per share for the current fiscal year.

Insider Activity at iRhythm Technologies

In other iRhythm Technologies news, insider Patrick Michael Murphy sold 2,478 shares of the business’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total transaction of $458,008.74. Following the sale, the insider directly owned 53,281 shares of the company’s stock, valued at $9,847,927.23. The trade was a 4.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Chad Patterson sold 280 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $51,752.40. Following the completion of the sale, the insider owned 43,387 shares of the company’s stock, valued at $8,019,219.21. The trade was a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.68% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its stake in iRhythm Technologies by 423.0% in the 1st quarter. Royal Bank of Canada now owns 7,573 shares of the company’s stock worth $793,000 after acquiring an additional 6,125 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of iRhythm Technologies by 33.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 433,780 shares of the company’s stock valued at $45,408,000 after purchasing an additional 108,941 shares during the period. Strs Ohio purchased a new stake in shares of iRhythm Technologies in the first quarter worth approximately $147,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of iRhythm Technologies by 13.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 2,410 shares of the company’s stock worth $371,000 after purchasing an additional 293 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its holdings in shares of iRhythm Technologies by 9.3% during the second quarter. Mutual of America Capital Management LLC now owns 22,652 shares of the company’s stock worth $3,488,000 after purchasing an additional 1,925 shares during the period.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.